Breast Cancer

Verzenio, or abemaciclib, marks a substantial advance in managing metastatic breast cancer, particularly for patients with HR-positive and HER2-negative subtypes. As a CDK4/6 inhibitor, it disrupts cancer cell proliferation, offering hope where previous therapies may have faltered. Understanding its benefits, side effects, and financial aspects is vital for patients navigating their cancer journey. Understanding Verzenio […]

Ibrance, known scientifically as palbociclib, offers a critical advance in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. When used alongside hormonal therapies, it effectively slows cancer progression but may bring side effects that require careful management. Understanding these potential side effects and the strategies to mitigate them is essential for patients. Additionally, awareness […]